What is Lifesci Capital’s Estimate for AURA FY2024 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at Lifesci Capital issued their FY2024 earnings estimates for Aura Biosciences in a report issued on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon expects that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.67) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at ($2.52) EPS.

Several other equities analysts also recently issued reports on the stock. Scotiabank lifted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. BTIG Research raised their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $7.89 on Friday. The company’s fifty day moving average is $8.38 and its 200-day moving average is $8.92. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The company has a market capitalization of $394.11 million, a PE ratio of -4.56 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. lifted its position in Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares during the period. Long Focus Capital Management LLC raised its holdings in shares of Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after buying an additional 561,766 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after buying an additional 39,379 shares during the last quarter. State Street Corp boosted its stake in Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after buying an additional 26,841 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after acquiring an additional 41,711 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Insider Buying and Selling at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 9,200 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total value of $98,808.00. Following the completion of the transaction, the insider now directly owns 320,647 shares of the company’s stock, valued at approximately $3,443,748.78. This trade represents a 2.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now directly owns 151,693 shares in the company, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,531 shares of company stock valued at $345,454. 5.40% of the stock is currently owned by corporate insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.